난소암에서 cyclin B1 및 D1 발현과임상 예후 인자들과의 관련성
Relationship between the expression of cyclin B1, D1 and the various prognostic factors in ovarian carcinoma
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
목적: 난소암에서 실시간 정량 역전사 중합효소 연쇄 반응 (quantitative real-time reverse transcriptase-polymerase chain reaction, quantitative real-time RT-PCR)을 이용한 cyclin B1과 D1의 mRNA 발현과 Western blot analysis를 이용한 cyclin B1과 D1의 단백질 발현을 연구하고 또한 이것과 여러 임상 예후 인자들과의 상관관계를 알아보고자 하였다. 연구 방법: 본원 산부인과에서 2002년 3월부터 2005년 2월까지 수술적 치료를 받은 환자를 대상으로 연구를 시행하여 신선한 난소암 조직 36예, 정상 난소 조직 5예를 얻었다. 결과: 실시간 정량 역전사 중합효소 연쇄 반응에 의한 난소암 조직에서의 cyclin B1과 D1 mRNA 2-△△CT 값의 평균은 각각 5.83±12.03과 17.60±22.20 였고, 대조군은 각각 0.55±0.35과 0.50±0.26로 두 군간에 차이를 보이나 통계적으로 유의하지 않았다 (p=0.67, p=0.07). Western blot analysis에 의한 cyclin B1과 D1 densitometer 값을 대조군에서 1로 보았을 때, 난소암 조직은 각각 1.30±0.73과 1.81±1.28로 두 군간에 차이를 보이나 통계적으로 유의하지 않았다. (p=0.76, p=0.06) Cyclin B1과 D1의 mRNA 및 단백질 발현은 임상 병리학적 예후 인자인 난소암의 외과적 병기, 혈청 내 CA-125, 유세포 분석법을 통한 DNA 정량검사 등과 통계적으로 상관관계를 보이지 않았다. 결론: 본 연구에서는 cyclin B1과 D1의 mRNA 및 단백질 발현이 난소암 조직에서 대조군보다 증가되어 cyclin B1과 D1이 난소의 종양형성 (tumorigenesis)과 악성도에 관여할 것으로 추정되었다. 그러나 cyclin B1과 D1의 mRNA 및 단백질 발현은 임상 병리학적 예후 인자들과 통계적으로 상관관계를 보이지 않았다. Cyclin이 난소암에서 예후 인자로서 가치가 있는지 평가하려면 발현 양상과 치료제에 대한 반응, 생존율 등을 연관시킨 연구가 뒷받침되어야 할 것으로 사료된다.
Abstract
Objective: The objective of this study was to evaluate the relationship between the expression of cyclin B1, D1 and the various prognostic factors in ovarian carcinoma. Methods: In this study, fresh ovarian tissue samples were obtained from 41 patients treated surgically at our institute from March of 2002 to February of 2005. These included 36 ovarian carcinomas and 5 normal ovarian tissues that were served as the control. Quantitative real-time RT-PCR and Western blot analysis were used in detecting the expression of mRNA and protein of cyclin B1, D1, respectively. Results: The mean 2-△△CT values of cyclin B1 and D1 mRNA in ovarian carcinoma tissues obtained through quantitative real-time RT-PCR were 5.83±12.03, 17.60±22.20, respectively, and the mean values in the control were 0.55±0.35, 0.50±0.26, respectively. The results showed difference in the expression, but were not statistically significant (p=0.67, 0.07, respectively). If the mean densitometer value of cyclin B1 and D1 protein in the control obtained by Western blot analysis was 1, the mean values in ovarian carcinoma tissues were higher, but were not statistically significant (1.30±0.73, 1.81±1.28, respectively) (p=0.76, 0.06, respectively). The expression of cyclin B1, D1 and various prognostic factors was not statistically related. Conclusion: Our results showed that the expression of cyclin B1 and D1 in ovarian carcinoma tissues was higher than in the normal control. This suggested that cyclin B1, D1 and the tumorigenesis and the degree of malignancy was closely related. But the expression of cyclin B1, D1 and various prognostic factors was not statistically related. Further studies based on the correlation between cyclin and response to treatment or survival rate are needed to support cyclin as a prognostic factor of ovarian carcinoma.
참고문헌 (39)
- "Annual Report of the Central Cancer Registry in Korea Central Cancer Registry Center in Korea Republic of Korea Ministry of Health and Welfare" (2003)
- Cannistra SA, "Cancer of the ovary", 329, pp.1550~9 (1993)
- Holschneider CH,, "epidemiology, biology, and prognostic factors. Semin Surg Oncol", 19, pp.3~10 (2000)
- Masciullo V, "Altered expression of cyclin D1 and CDK4 genes in ovarian carcinomas", 74, pp.390~5 (1997)
- Sigurdsson K, "Prognostic factors in malignant epithelial ovarian tumors", 15, pp.370~80 (1983)
- Rustin GJ, "Defining progression of ovarian carcinoma during follow-up according to CA 125:a North Thames Ovary Group Study", 7, pp.361~4 (1996)
- Friedlander ML, "Prediction of long-term survival by flow cytometric analysis of cellular DNA content in patients with advanced ovarian cancer", 6, pp.282~90 (1988)
- Meyer JS, "Cell proliferation in ovarian carcinoma superior accuracy of S-phase fraction lack of independent prognostic power for SPF and DNA ploidy and limited effect of SPF on tumor growth rate", 81, pp.466~76 (2001)
- Omura GA, "Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma:the Gynecologic Oncology Group experience", 9, pp.1138~50 (1991)
- Mattila J, "Prognostic significance of DNA index and S-phase fraction in ovarian cancer", pun(nen r), pp.334~9
- Eisenhauer EA, "should we be managing patients with good and bad prognostic factors in the same manner? Ann Oncol 1999", 10(1), pp.9~15 (1999)
- Clark TG, "A prognostic model for ovarian cancer", 85, pp.944~52 (2001)
- Sherr CJ, "Cancer cell cycles. Science (Washington DC", 274, pp.1672~7 (1996)
- Champeme MH, "11q13 amplification in local recurrence of human primary breast cancer", 12, pp.128~33 (1995)
- Jiang W, "Amplification and expression of the human cyclin D gene in esophageal cancer", 52, pp.2980~3 (1992)
- Kawamoto H, "Expression of the G2-M checkpoint regulators cyclin B1 and cdc2 in nonmalignant and malignant human breast lesions:immunocytochemical and quantitative image analyses", 150, pp.15~23 (1997)
- Wang A, "Overexpression of cyclin B1 in human colorectal cancers", 123, pp.124~7 (1997)
- Murakami H, "Determination of the prognostic significance of cyclin B1 overexpression in patients with esophageal squamous cell carcinoma", 434, pp.153~8 (1999)
- Soria JC, "Overexpression of cyclin B1 in early-stage non-small cell lung cancer and its clinical implication", 60, pp.4000~4 (2000)
- Allan K, "Overexpression of cyclin A and cyclin B1 proteins in astrocytomas", 124, pp.216~20 (2000)
- Dutta A, "Cyclins as markers of tumor proliferation immunocytochemical studies in breast cancer", 92, pp.5386~90 (1995)
- Welsh JB, "Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer", 98, pp.1176~81 (2001)
- Sherr CJ, "Inhibitors of mammalian G1 cyclin-dependent kinases", 9, pp.1149~63 (1995)
- D'Andrilli G, "Cell cycle genes in ovarian cancer:steps toward earlier diagnosis and novel therapies", 10, pp.8132~41 (2004), Clin Cancer Res
- Yoshioka S, "Expressions of cyclin E and B1 in Hodgkin and Reed- Sternberg cells not suppressed by cyclin-dependent kinase inhibitor p21 expression", 49, pp.506~12 (1999)
- Ito M, "Factors controlling cyclin B expression", 43, pp.677~90 (2000)
- Worsley SD, "Overexpression of cyclin D1 in epithelial ovarian cancers", 64, pp.189~95 (1997)
- Hung WC, "Expression of cyclin D1 and c-Ki-ras gene product in human epithelial ovarian tumors", 27, pp.1324~8 (1996)
- Barbieri F, "Expression of cyclin D1 correlates with malignancy in human ovarian tumours", 75, pp.1263~8 (1997)
- Bartkova J, "Cyclin D1 protein expression and function in human breast cancer", 57, pp.353~61 (1994)
- Bellacosa A, "Cyclin D1 gene amplification in human laryngeal squamous cell carcinomas:prognostic significance and clinical implications", 2, pp.175~80 (1996), Clin Cancer Res
- Gillett C, "Cyclin D1 and prognosis in human breast cancer", 69, pp.92~9 (1996)
- Tamimi Y, "Expression of cyclin D1 and EMS1 in bladder tumours relationship with chromosome 11q13 amplification", 12, pp.1747~53 (1996)
- Pines J, "Human cyclin A is adenovirus E1A-associated protein p60 and behaves differently from cyclin B", 346, pp.760~3 (1990)
- Pines J, "The differential localization of human cyclins A and B is due to a cytoplasmic retention signal in cyclin B", 13, pp.3772~81 (1994)
- Pines J, "Isolation of a human cyclin cDNA:evidence for cyclin mRNA and protein regulation in the cell cycle and for interaction with p34cdc2", 58, pp.833~46 (1989)
- Hwang A, "Cell cycle-dependent usage of transcriptional start sites A novel mechanism for regulation of cyclin B1", 273, pp.31505~9 (1998)
- Park M, "Constitutive activation of cyclin B1-associated cdc2 kinase overrides p53-mediated G2-M arrest", 60, pp.542~5 (2000)
- Innocente SA, "p53 regulates a G2 checkpoint through cyclin B1", 96, pp.2147~52 (1999)